Breaking News
December 18, 2018 - Weight change in middle-aged, elderly Chinese Singaporeans related to increased risk of death
December 18, 2018 - Immune cells sacrifice themselves to protect us from invading bacteria
December 18, 2018 - Watching brain cells fire, with a twist of gravitational waves
December 18, 2018 - 2018 in Review
December 18, 2018 - Getting the Most Out of the CLARITY Technique
December 18, 2018 - NVF shoes provide a viable option for track and road racing
December 18, 2018 - CRISPR may restore effectiveness of chemotherapies used to treat lung cancer
December 18, 2018 - New app accurately measures and charts progression of skin wounds
December 18, 2018 - Persistent Discrimination ID’d Among Physician Mothers
December 18, 2018 - Cellphone technology developed to detect HIV
December 18, 2018 - A Stanford doctor hits the field with the 49ers — as their airway management physician
December 18, 2018 - The Rise of Anxiety Baking
December 18, 2018 - Just one night of sleep deprivation increases the urge to eat
December 18, 2018 - Study reveals mechanism behind failed remyelination in MS
December 18, 2018 - New genetic testing method increases the precision of biomarker analysis
December 18, 2018 - Simple technique to effectively treat underdiagnosed cause of debilitating chest pain
December 18, 2018 - Barbershop-based medical intervention can successfully lower blood pressure, new data shows
December 18, 2018 - Food labels have caused changes in consumers’ intake and industry’s use of key additives
December 18, 2018 - Sickest children could benefit from split liver transplants
December 18, 2018 - Scientists create patient-specific model to identify most effective treatment for appendix cancer
December 18, 2018 - Researchers discover promising new compound against Buruli ulcer
December 18, 2018 - Study finds significant use of traditional, complementary and alternative medicines in Sub-Saharan Africa
December 18, 2018 - California Farm Implicated in Outbreak of E. coli Tied to Romaine Lettuce
December 18, 2018 - Mobile health has power to transform HIV/AIDS nursing
December 18, 2018 - Celiac Vaccine in Clinical Trials at Columbia
December 18, 2018 - Research into mental health first aid prompts practical guidance and resources for workplace
December 18, 2018 - Researcher conducts study to investigate peripheral blood markers of Alzheimer’s disease
December 18, 2018 - Researchers identify link between mucus in the small airways and pulmonary fibrosis
December 18, 2018 - EU Commission’s Health Policy Platform to host EKHA program on transplantation
December 18, 2018 - Survivors of childhood Hodgkin lymphoma have high risk of developing solid tumors
December 18, 2018 - Small changes to cafeteria design can get kids to eat healthier, new assessment tool finds
December 18, 2018 - From Machines to Cyclic Compounds
December 18, 2018 - New study reveals best assessment tools to establish delirium severity
December 18, 2018 - Rice University scientists develop synthetic protein switches to control electron flow
December 18, 2018 - Home-based pulmonary function monitoring for teens with Duchenne muscular dystrophy
December 18, 2018 - Researchers identify potential target for new breast cancer treatments
December 18, 2018 - National Biofilms Innovation Centre award grant to Neem Biotech for novel anti-biofilm drug development
December 18, 2018 - Artificial intelligence and the future of medicine
December 18, 2018 - Montana State doctoral student receives grant for her work to improve neuroscience tool
December 18, 2018 - Early postpartum initiation of opioids associated with persistent use
December 18, 2018 - Russian scientists identify molecular ‘switch’ that could be target for treatment of allergic asthma
December 18, 2018 - Surgeons make more mistakes in the operating room during stressful moments, shows study
December 18, 2018 - Immune cells explode themselves to inform about the danger of invading bacteria
December 18, 2018 - Malnutrition in children with Crohn’s disease linked with increased risk of surgical complications
December 18, 2018 - FDA Approves Motegrity (prucalopride) for Adults with Chronic Idiopathic Constipation (CIC)
December 18, 2018 - The long and short of CDK12
December 18, 2018 - Hologic’s Cynosure division introduces TempSure Surgical RF technology in North America
December 18, 2018 - CMR Surgical partners with Nicholson Center to launch U.S.-based training program for Versius
December 18, 2018 - Findings reinforce guidelines for cautious use of antipsychotics in younger populations
December 18, 2018 - Study finds new strains of hepatitis C virus in sub-Saharan Africa
December 18, 2018 - New battery-free, implantable device aids weight loss
December 18, 2018 - Parental alcohol use disorder associated with offspring marital outcomes
December 18, 2018 - Novel Breast Imaging Technique Might Cut Unnecessary Biopsies
December 18, 2018 - What can a snowflake teach us about how cancer spreads in the body?
December 18, 2018 - Management of nausea and vomiting in pregnancy costs the NHS more than previously thought
December 18, 2018 - Green leafy vegetables may reduce risk of developing liver steatosis
December 18, 2018 - Veganism linked to nutrient deficiencies and malnutrition if not planned correctly
December 18, 2018 - Coming Soon: A Tiny Robot You Swallow to Help You Stay Healthy
December 18, 2018 - Modified malaria drug proven effective at inhibiting Ebola
December 18, 2018 - Study finds epigenetic differences in the brains of individuals with schizophrenia
December 18, 2018 - Fitness instructors’ motivational comments influence women’s body satisfaction
December 18, 2018 - Study focuses on modification of lipid nanoparticles for successful brain cell targeting
December 18, 2018 - New gut bacteria may be effective against obesity, metabolic and mental disorders
December 18, 2018 - New two-in-one powder aerosol to upgrade fight against deadly superbugs in lungs
December 18, 2018 - Biofilms feed with swirling flows
December 17, 2018 - Study identifies specific neurological changes related to traumatic brain injury
December 17, 2018 - New study confirms geographic bias in lung allocation for transplant
December 17, 2018 - Research focuses on optimization of solid lipid nanoparticle that encapsulates Vinorelbine bitartrate
December 17, 2018 - Carpal tunnel syndrome – Genetics Home Reference
December 17, 2018 - A novel insulin accelerant
December 17, 2018 - Tips for caring for patients with disabilities, from a mother and physician
December 17, 2018 - Menopause-related sexual, urinary problems tied to worse quality of life
December 17, 2018 - In-school nutrition programs among students limit increases in BMI, finds study
December 17, 2018 - Risk for Hospitalization for Heart Failure Greater With Diabetes
December 17, 2018 - Food assistance may help older adults adhere to diabetes meds
December 17, 2018 - Supporting a family’s goals during a difficult pregnancy
December 17, 2018 - Neurons with Good Housekeeping Are Protected from Alzheimer’s
December 17, 2018 - New approach to tumor analysis could improve prognosis for bowel cancer patients
December 17, 2018 - New ‘epigenetics-based’ cervical cancer test outperforms Pap smear and HPV tests
December 17, 2018 - Ten year follow-up after negative colonoscopy related to reduced risk of colorectal cancer
‘Soft’ Chemo Plus Targeted Therapy Works in HER2 Breast Cancer

‘Soft’ Chemo Plus Targeted Therapy Works in HER2 Breast Cancer

image_pdfDownload PDFimage_print

Action Points

  • Note that this randomized trial found that the addition of the somewhat “gentle” chemotherapy metronomic oral cyclophosphamide to pertuzumab and trastuzumab increased progression-free survival among older women with HER-2 positive breast cancer.
  • Be aware that these patients were all either over 70 years old, or over 60 with certain functional limitations.

A combination of “soft” chemotherapy and anti-HER2 therapy is effective in older patients with HER2-positive metastatic breast cancer and comes with an acceptable safety profile, investigators have found.

Specifically, they determined that the use of trastuzumab and pertuzumab with the “softer” chemotherapy metronomic oral cyclophosphamide provided patients with seven months longer progression-free survival compared to patients who were treated with trastuzumab and pertuzumab alone.

The study, led by Hans Wildiers, MD, PhD, University Hospitals Leuven, in Belgium, was published in The Lancet Oncology.

As pointed out by Wildiers and his colleagues, while HER2-positive metastatic breast cancer is particularly aggressive if left untreated, advances in HER2-directed drug development have resulted in improvements in outcomes.

For example, the phase 3 CLEOPATRA Trial showed that the addition of trastuzumab to pertuzumab and the chemotherapy drug docetaxel significantly improved progression-free survival, as well as overall survival.

While docetaxel combined with trastuzumab and pertuzumab has been shown to be effective in younger patients with HER2 positive metastatic breast cancer, it can be significantly toxic and affect quality of life, particularly in older patients.

The question Wildiers and his colleagues wanted to address was whether the introduction of HER2–directed therapies makes it possible to treat older HER2-positive metastatic breast cancer patients with HER2-targeted regimens and without classical therapies.

They pointed out that the dual blockade of HER2 with trastuzumab and pertuzumab has shown substantial anti-tumor activity. At the same time metronomic chemotherapy with oral cyclophosphamide has shown antitumor activity with minimal toxicity, making it more suitable for older patients.

“Given the need to develop new treatment strategies with limited toxicity for older patients with breast cancer, we aimed to examine the safety and activity of dual anti-HER2 treatment with or without metronomic chemotherapy in this population,” Wildiers and his colleagues wrote.

In this open-label, randomized, phase II trial, 80 patients were randomly assigned to receive trastuzumab and pertuzumab (TP) or TP plus metronomic oral cyclophosphamide (TPM). The patients were 70 years of age or older, or 60 years or older if they presented with certain functional limitations. The median age of the study participants was 76.7 years.

Wildiers and his colleagues found that estimated progression-free survival at 6 months was 46.2% (95% CI, 30.2-60.7) with TP alone compared to 73.4% (95% CI, 56.6-84.6) with TPM. At a median follow-up of 20.7 months, the median progression-free survival was 5.6 months (95% CI, 3.6-16.8) in the TP group versus 12.7 months (95% CI, 6.7-24.8) in the TPM group.

The most frequent grade 3-4 adverse events included hypertension (in 6 [15%] of 39 patients in the trastuzumab and pertuzumab group versus 5 [12%] of 41 in the trastuzumab and pertuzumab plus metronomic oral cyclophosphamide group), diarrhea (4 [10%] versus 5 [12%]), dyspnea (2 [5%] versus 4 [10%]), fatigue (3 [8%] versus 2 [5%]), pain (2 [5%] versus 2 [5%]), and a thromboembolic event (0 [0%] versus 4 [10%]).

In a press release Wildiers called the results “encouraging,” since he and his colleagues were able to show that the use of gentle therapy among older, frail patients could delay tumor growth while delaying or even avoiding the use of more toxic chemotherapy.

“In this age group, maintenance of [quality of life] and the avoidance of toxic side-effects may be just as important as survival,” he said.

“We believe that there is a strong case for carrying out trials designed specifically for older people,” Wildiers added. “However, financial support for such trials is very difficult to find. Additionally, older patients are far less likely to receive standard chemotherapy, and are also unlikely to be included in a randomized trial where there is a risk that they will receive a treatment with high toxicity.”

In a commentary accompanying the study, Charles E. Geyer, MD, Massey Cancer Center, Virginia Commonwealth University, also noted that while clinical trials are a prerequisite for establishing new treatment standards, “eligibility criteria generally restrict participation to fit populations with minimal comorbidities,” which, in turn, results in the underrepresentation in clinical trials of older patients with functional limitations.

Thus, Wildiers and his colleagues “are to be congratulated on their demonstration of a framework for clinical trials in older, more frail patients with HER-positive-metastatic breast cancer,” wrote Geyer.

Wildiers reports research grants from Roche and personal fees towards his institute from Roche, Amgen, Novartis, Pfizer, Puma, and Celldex. Geyer has received personal fees from Myriad and Heron Therapeutics for advisory board participation and travel support from AstraZeneca, Genentech, and Macrogenics, outside the submitted work.

  • Reviewed by
    F. Perry Wilson, MD, MSCE Assistant Professor, Section of Nephrology, Yale School of Medicine and Dorothy Caputo, MA, BSN, RN, Nurse Planner

2018-12-02T00:00:00-0500

last updated

Tagged with:

About author

Related Articles